Today, Campaign for Accountability filed a complaint with the Securities and Exchange Commission requesting an investigation into Natera Inc., a clinical genetic testing company. Following New York Times reporting on the company’s prenatal tests, CfA alleges that Natera appears to have misled investors about the accuracy of its prenatal genetic tests and failed to disclose the investor risk associated with tests resulting in false positives.